A Study of ARRY-371797 in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: ARRY-371797, p38 inhibitor; oralDrug: Placebo; oral
- Registration Number
- NCT00729209
- Lead Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Brief Summary
This is a Phase 1 study, involving a 29-day treatment period, designed to evaluate the pharmacokinetics and the effectiveness of investigational study drug ARRY-371797 in treating rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further evaluate the drug's safety. Approximately 30 patients from the US will be enrolled in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 28
- Diagnosed with rheumatoid arthritis (RA) at least 3 months prior to study start based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
- On a stable weekly dose of both methotrexate (MTX) (10 - 25 mg/week inclusively; either oral or parenteral) and folate (≥ 5 mg weekly ) for ≥ 6 weeks prior to study start and is willing to continue on these regimens for the duration of the study.
- Meets the ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II, or III.
- Completed an appropriate washout period if treated with specified therapies.
- Patients may continue on specified stable background therapy for RA (doses should be stable for at least 6 weeks prior to the first dose of study drug, unless the patient stops due to documented disease improvement, with Sponsor approval).
- Additional criteria exist.
Key
-
Diagnosis of any other inflammatory or non-inflammatory arthritis (e.g. spondyloarthritis; fibromyalgia, psoriatic arthritis, crystal-proven gout) that may interfere with disease activity assessments and/or clinically apparent osteoarthritis which would affect subsequent efficacy measures.
-
Has received any of the following prior treatments:
- Within 4 weeks of first dose of study drug: anakinra (Kineret®), etanercept (Enbrel®);
- Within 8 weeks of first dose of study drug: infliximab (Remicade®), adalimumab (Humira®), leflunomide (Arava®);
- At any time: rituximab (Rituxan®), alemtuzumab (CamPath®), any experimental B cell targeting agents.
-
Treatment with potent CYP3A inhibitors or inducers, disease-modifying antirheumatic drugs (DMARDs) and/or biologic response modifiers (BRMs) during the study.
-
Additional criteria exist.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ARRY-371797 (Schedule 1) ARRY-371797, p38 inhibitor; oral - Placebo Placebo; oral - ARRY-371797 (Schedule 2) ARRY-371797, p38 inhibitor; oral -
- Primary Outcome Measures
Name Time Method Characterize the pharmacokinetics (PK) of the study drug and a metabolite in terms of plasma concentrations. 29 days
- Secondary Outcome Measures
Name Time Method Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms. 29 days Assess the efficacy of study drug (versus placebo) in terms of cross-reactive protein (CRP), the Patient's Assessment of Arthritis Pain (100 mm visual analog scale [VAS]) and urinary N-Telopeptide Cross-Links (NTx). 29 days
Trial Locations
- Locations (7)
Metroplex Clinical Research Center
🇺🇸Dallas, Texas, United States
Clinic for Rheumatic Diseases
🇺🇸Tuscaloosa, Alabama, United States
Sentara Clinical Research Group
🇺🇸Norfolk, Virginia, United States
Lynn Health Sciences Institute
🇺🇸Oklahoma City, Oklahoma, United States
NUCATS Institute, Northwestern University
🇺🇸Chicago, Illinois, United States
Woodland International Research Group
🇺🇸Little Rock, Arkansas, United States
Sun Valley Arthritis Center, Ltd
🇺🇸Peoria, Arizona, United States